Literature DB >> 20980993

A dopamine D1 receptor-dependent β-arrestin signaling complex potentially regulates morphine-induced psychomotor activation but not reward in mice.

Nikhil M Urs1, Tanya L Daigle, Marc G Caron.   

Abstract

Morphine is a widely used analgesic in humans that is associated with multiple untoward effects, such as addiction and physical dependence. In rodent models, morphine also induces locomotor activity. These effects likely involve functionally selective mechanisms. Indeed, G protein-coupled receptor desensitization and adaptor protein β-arrestin 2 (βarr2) through its interaction with the μ-opioid receptor regulates the analgesic but not the rewarding properties of morphine. However, βarr2 is also required for morphine-induced locomotor activity in mice, but the exact cellular and molecular mechanisms that mediate this arrestin-dependent behavior are not understood. In this study, we show that βarr2 is required for morphine-induced locomotor activity in a dopamine D1 receptor (D1R)-dependent manner and that a βarr2/phospho-ERK (βarr2/pERK) signaling complex may mediate this behavior. Systemic administration of SL327, an MEK inhibitor, inhibits morphine-induced locomotion in wild-type mice in a dose-dependent manner. Acute morphine administration to mice promotes the formation of a βarr2/pERK signaling complex. Morphine-induced locomotor activity and formation of the βarr2/pERK signaling complex is blunted in D1R knockout (D1-KO) mice and is presumably independent of D2 dopamine receptors. However, D1Rs are not required for morphine-induced reward as D1-KO mice show the same conditioned place preference for morphine as do control mice. Taken together, these results suggest a potential role for a D1R-dependent βarr2/pERK signaling complex in selectively mediating the locomotor-stimulating but not the rewarding properties of morphine.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20980993      PMCID: PMC3021093          DOI: 10.1038/npp.2010.186

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  40 in total

1.  Role for G protein-coupled receptor kinase in agonist-specific regulation of mu-opioid receptor responsiveness.

Authors:  J Zhang; S S Ferguson; L S Barak; S R Bodduluri; S A Laporte; P Y Law; M G Caron
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

2.  Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia.

Authors:  I Sora; N Takahashi; M Funada; H Ujike; R S Revay; D M Donovan; L L Miner; G R Uhl
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

Review 3.  Dopamine receptors: from structure to function.

Authors:  C Missale; S R Nash; S W Robinson; M Jaber; M G Caron
Journal:  Physiol Rev       Date:  1998-01       Impact factor: 37.312

4.  Enhanced morphine analgesia in mice lacking beta-arrestin 2.

Authors:  L M Bohn; R J Lefkowitz; R R Gainetdinov; K Peppel; M G Caron; F T Lin
Journal:  Science       Date:  1999-12-24       Impact factor: 47.728

5.  beta-Arrestin1 knockout mice appear normal but demonstrate altered cardiac responses to beta-adrenergic stimulation.

Authors:  D A Conner; M A Mathier; R M Mortensen; M Christe; S F Vatner; C E Seidman; J G Seidman
Journal:  Circ Res       Date:  1997-12       Impact factor: 17.367

6.  Loss of autoreceptor functions in mice lacking the dopamine transporter.

Authors:  S R Jones; R R Gainetdinov; X T Hu; D C Cooper; R M Wightman; F J White; M G Caron
Journal:  Nat Neurosci       Date:  1999-07       Impact factor: 24.884

7.  Stable interaction between beta-arrestin 2 and angiotensin type 1A receptor is required for beta-arrestin 2-mediated activation of extracellular signal-regulated kinases 1 and 2.

Authors:  Huijun Wei; Seungkirl Ahn; William G Barnes; Robert J Lefkowitz
Journal:  J Biol Chem       Date:  2004-09-07       Impact factor: 5.157

Review 8.  Akt/GSK3 signaling in the action of psychotropic drugs.

Authors:  Jean-Martin Beaulieu; Raul R Gainetdinov; Marc G Caron
Journal:  Annu Rev Pharmacol Toxicol       Date:  2009       Impact factor: 13.820

9.  Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter.

Authors:  B Giros; M Jaber; S R Jones; R M Wightman; M G Caron
Journal:  Nature       Date:  1996-02-15       Impact factor: 49.962

10.  Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice.

Authors:  M A Kelly; M Rubinstein; S L Asa; G Zhang; C Saez; J R Bunzow; R G Allen; R Hnasko; N Ben-Jonathan; D K Grandy; M J Low
Journal:  Neuron       Date:  1997-07       Impact factor: 17.173

View more
  60 in total

1.  Identification of G protein-biased agonists that fail to recruit β-arrestin or promote internalization of the D1 dopamine receptor.

Authors:  Jennie L Conroy; R Benjamin Free; David R Sibley
Journal:  ACS Chem Neurosci       Date:  2015-02-20       Impact factor: 4.418

2.  D1 dopamine receptors intrinsic activity and functional selectivity affect working memory in prefrontal cortex.

Authors:  Yang Yang; Sang-Min Lee; Fumiaki Imamura; Krishne Gowda; Shantu Amin; Richard B Mailman
Journal:  Mol Psychiatry       Date:  2018-12-07       Impact factor: 15.992

Review 3.  Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance.

Authors:  Kirsten M Raehal; Cullen L Schmid; Chad E Groer; Laura M Bohn
Journal:  Pharmacol Rev       Date:  2011-08-26       Impact factor: 25.468

Review 4.  Disentangling the diverse roles of dopamine D2 receptors in striatal function and behavior.

Authors:  Eduardo F Gallo
Journal:  Neurochem Int       Date:  2019-02-01       Impact factor: 3.921

5.  Identification of Positive Allosteric Modulators of the D1 Dopamine Receptor That Act at Diverse Binding Sites.

Authors:  Kathryn D Luderman; Jennie L Conroy; R Benjamin Free; Noel Southall; Marc Ferrer; Marta Sanchez-Soto; Amy E Moritz; Blair K A Willette; Tim J Fyfe; Prashi Jain; Steve Titus; Lisa A Hazelwood; Jeffrey Aubé; J Robert Lane; Kevin J Frankowski; David R Sibley
Journal:  Mol Pharmacol       Date:  2018-08-01       Impact factor: 4.436

6.  Characterization of [(3) H]LS-3-134, a novel arylamide phenylpiperazine D3 dopamine receptor selective radioligand.

Authors:  Claudia Rangel-Barajas; Maninder Malik; Michelle Taylor; Kim A Neve; Robert H Mach; Robert R Luedtke
Journal:  J Neurochem       Date:  2014-08-19       Impact factor: 5.372

7.  (-)-Stepholidine is a potent pan-dopamine receptor antagonist of both G protein- and β-arrestin-mediated signaling.

Authors:  Julie A Meade; R Benjamin Free; Nicole R Miller; Lani S Chun; Trevor B Doyle; Amy E Moritz; Jennie L Conroy; Val J Watts; David R Sibley
Journal:  Psychopharmacology (Berl)       Date:  2014-09-18       Impact factor: 4.530

8.  SKF-83959 is not a highly-biased functionally selective D1 dopamine receptor ligand with activity at phospholipase C.

Authors:  Sang-Min Lee; Andrew Kant; Daniel Blake; Vishakantha Murthy; Kevin Boyd; Steven J Wyrick; Richard B Mailman
Journal:  Neuropharmacology       Date:  2014-06-12       Impact factor: 5.250

9.  Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.

Authors:  Nikhil M Urs; Simone Bido; Sean M Peterson; Tanya L Daigle; Caroline E Bass; Raul R Gainetdinov; Erwan Bezard; Marc G Caron
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-27       Impact factor: 11.205

10.  Dopamine D1 receptors are not critical for opiate reward but can mediate opiate memory retrieval in a state-dependent manner.

Authors:  Ryan Ting-A-Kee; Laura E Mercuriano; Hector Vargas-Perez; Susan R George; Derek van der Kooy
Journal:  Behav Brain Res       Date:  2013-03-26       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.